FDMT
4D Molecular Therapeutics, Inc.NASDAQHealthcare$9.48-3.95%ClosedMarket Cap: $484.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.14
P/S
5.96
EV/EBITDA
-2.94
DCF Value
$-10.47
FCF Yield
-21.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-14.0%
Operating Margin
-187.2%
Net Margin
-164.4%
ROE
-31.7%
ROA
-24.7%
ROIC
-30.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $85.1M | 97.7% | $14.7M | $19.4M | $0.34 | — |
| FY 2025 | $85.2M | 91.1% | $-159.5M | $-140.1M | $-2.42 | — |
| Q3 2025 | $90.0K | -52386.7% | $-61.2M | $-56.9M | $-1.01 | — |
| Q2 2025 | $15.0K | -319573.3% | $-59.5M | $-54.7M | $-0.98 | — |
| Q1 2025 | $14.0K | 100.0% | $-53.6M | $-48.0M | $-0.86 | — |
| Q4 2024 | $1.0K | -178300.0% | $-56.1M | $-49.7M | $-0.90 | — |
| FY 2024 | $37.0K | 100.0% | $-187.8M | $-160.9M | $-2.98 | — |
| Q3 2024 | $3.0K | 100.0% | $-51.1M | $-43.8M | $-0.79 | — |
| Q2 2024 | $5.0K | -637100.0% | $-42.5M | $-35.0M | $-0.63 | — |
| Q1 2024 | $28.0K | -99435.7% | $-38.1M | $-32.4M | $-0.66 | — |
| Q4 2023 | $-19.0K | 137089.5% | $-36.7M | $-32.3M | $-0.83 | — |
| FY 2023 | $20.7M | -368.5% | $-112.9M | $-100.8M | $-2.58 | — |